Cantor Fitzgerald restated their buy rating on shares of BioDelivery Sciences International (NASDAQ:BDSI) in a report issued on Thursday. They currently have a $5.00 target price on the specialty pharmaceutical company’s stock.
“. After a day of meetings with BDSI CEO Herm Cukier earlier this week, we are reiterating our Overweight rating and 12-month price target of $5. We view BDSI as a Belbuca execution story, and, based on Symphony script data so far in 2018, the company is exceeding its execution goals as well as our expectations. The sentiment at the meetings was positive with a common theme of delving into whether the company has the foundation to continue to execute in 2019 as it has in 2018. Following the meetings, we have increased conviction that solid execution in 2019 and beyond is likely to continue, which should drive upward earnings revisions and further upside in BDSI stock. Detailed takeaways are below.”,” the firm’s analyst wrote.
Several other research firms have also commented on BDSI. HC Wainwright reissued a buy rating and set a $5.00 price target on shares of BioDelivery Sciences International in a research report on Friday, November 2nd. Janney Montgomery Scott boosted their price target on BioDelivery Sciences International to $5.00 and gave the stock a buy rating in a research report on Friday, November 2nd. BidaskClub raised BioDelivery Sciences International from a sell rating to a hold rating in a research report on Friday, December 7th. Finally, Zacks Investment Research lowered BioDelivery Sciences International from a buy rating to a hold rating in a research report on Monday, October 15th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. BioDelivery Sciences International presently has a consensus rating of Buy and a consensus price target of $4.54.
BioDelivery Sciences International stock opened at $3.55 on Thursday. The company has a debt-to-equity ratio of 1.42, a quick ratio of 2.77 and a current ratio of 3.00. BioDelivery Sciences International has a one year low of $1.70 and a one year high of $4.14.
BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04. The firm had revenue of $14.16 million for the quarter, compared to analyst estimates of $14.21 million. BioDelivery Sciences International had a negative return on equity of 141.35% and a negative net margin of 85.93%. On average, research analysts expect that BioDelivery Sciences International will post -0.61 earnings per share for the current fiscal year.
In other BioDelivery Sciences International news, Director Francis E. Odonnell, Jr. sold 8,000 shares of the company’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $3.72, for a total value of $29,760.00. Following the transaction, the director now directly owns 514,187 shares of the company’s stock, valued at approximately $1,912,775.64. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Paolantonio Ernest Robert De sold 16,161 shares of the company’s stock in a transaction that occurred on Tuesday, December 4th. The shares were sold at an average price of $3.79, for a total value of $61,250.19. Following the completion of the transaction, the chief financial officer now directly owns 140,548 shares in the company, valued at $532,676.92. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 40,161 shares of company stock worth $143,730. 13.26% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in BDSI. Bank of Montreal Can acquired a new position in shares of BioDelivery Sciences International in the 2nd quarter valued at approximately $138,000. Royce & Associates LP raised its position in shares of BioDelivery Sciences International by 19.1% in the 2nd quarter. Royce & Associates LP now owns 2,200,800 shares of the specialty pharmaceutical company’s stock valued at $6,492,000 after purchasing an additional 352,200 shares in the last quarter. BlackRock Inc. raised its position in shares of BioDelivery Sciences International by 2.7% in the 2nd quarter. BlackRock Inc. now owns 1,190,286 shares of the specialty pharmaceutical company’s stock valued at $3,512,000 after purchasing an additional 30,991 shares in the last quarter. PNC Financial Services Group Inc. acquired a new position in shares of BioDelivery Sciences International in the 2nd quarter valued at approximately $148,000. Finally, Cortina Asset Management LLC acquired a new position in shares of BioDelivery Sciences International in the 2nd quarter valued at approximately $5,629,000. 53.16% of the stock is currently owned by institutional investors.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Further Reading: Average Daily Trade Volume – ADTV
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.